OtherJun 18, 2026, 04:32 PM
Medtronic Files 2026 Form 10-K Annual Report
AI Summary
Medtronic plc filed its annual report on Form 10-K, detailing its business operations across its Cardiovascular, Neuroscience, and Medical Surgical portfolios. A significant event noted is the separation of its Diabetes Business, which was completed through an IPO of MiniMed Group, Inc. in March 2026. The report emphasizes Medtronic's mission and strategic focus on innovation, patient outcomes, and leveraging technology like AI and data analytics. It provides an overview of the company's diverse product lines and its commitment to human capital management and research and development.
Key Highlights
- Medtronic plc filed its annual report on Form 10-K on June 18, 2026.
- The report details the company's business segments: Cardiovascular, Neuroscience, and Medical Surgical.
- Medtronic announced the intent to separate its Diabetes Business, creating MiniMed Group, Inc., which completed an IPO in March 2026.
- The company's mission is to alleviate pain, restore health, and extend life through biomedical engineering.
- Key strategic areas include accelerating innovation, delivering superior patient and provider outcomes, and leveraging data, AI, and automation.
- The report outlines various products within its Cardiovascular Portfolio, including pacemakers, ICDs, and aortic valves.
- The Neuroscience Portfolio includes products for neurosurgery, spinal conditions, and neuromodulation.
- The Medical Surgical Portfolio covers surgical and endoscopy products, as well as acute care and monitoring solutions.
Price Impact
More from MDT